IL-6 overexpression in ERG-Positive prostate cancer is mediated by prostaglandin receptor EP2 / Constanze Merz, Anne von Mässenhausen, Angela Queisser, Wenzel Vogel, Ove Andrén, Jutta Kirfel, Stefan Duensing, Sven Perner, and Michael Nowak
Prostate cancer is the most diagnosed cancer in men and multiple risk factors and genetic alterations have been described. The TMPRSS2-ERG fusion event and the overexpression of the transcription factor ERG are present in approximately 50% of all prostate cancer patients, however, the clinical outcome is still controversial. Prostate tumors produce various soluble factors, including the pleiotropic cytokine IL-6, regulating cellular processes such as proliferation and metastatic segregation. Here, we used prostatectomy samples in a tissue microarray format and analyzed the co-expression and the clinicopathologic data of ERG and IL-6 using immunohistochemical double staining and correlated the read-out with clinicopathologic data. Expression of ERG and IL-6 correlated strongly in prostate tissue samples. Forced expression of ERG in prostate tumor cell lines resulted in significantly increased secretion of IL-6, whereas the down-regulation of ERG decreased IL-6 secretion. By dissecting the underlying mechanism in prostate tumor cell lines we show the ERG-mediated up-regulation of the prostanoid receptors EP2 and EP3. The prostanoid receptor EP2 was overexpressed in human prostate cancer tissue. Furthermore, the proliferation rate and IL-6 secretion in DU145 cells was reduced after treatment with EP2-receptor antagonist. Collectively, our study shows that the expression of ERG in prostate cancer is linked to the expression of IL-6 mediated by the prostanoid receptor EP2..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
April 2016 2016 |
|---|---|
| Erschienen: |
April 2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:186 |
|---|---|
| Enthalten in: |
The American journal of pathology - 186(2016), 4, Seite 974-984 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Merz, Constanze, 1969- [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
Gesehen am 04.05.2020 |
|---|
| Umfang: |
11 |
|---|
| doi: |
10.1016/j.ajpath.2015.12.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
1697017703 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | 1697017703 | ||
| 003 | DE-627 | ||
| 005 | 20230427121954.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200504s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ajpath.2015.12.009 |2 doi | |
| 035 | |a (DE-627)1697017703 | ||
| 035 | |a (DE-599)KXP1697017703 | ||
| 035 | |a (OCoLC)1341317972 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Merz, Constanze |d 1969- |e verfasserin |0 (DE-588)122527445 |0 (DE-627)705940187 |0 (DE-576)293308896 |4 aut | |
| 245 | 1 | 0 | |a IL-6 overexpression in ERG-Positive prostate cancer is mediated by prostaglandin receptor EP2 |c Constanze Merz, Anne von Mässenhausen, Angela Queisser, Wenzel Vogel, Ove Andrén, Jutta Kirfel, Stefan Duensing, Sven Perner, and Michael Nowak |
| 264 | 1 | |c April 2016 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 04.05.2020 | ||
| 520 | |a Prostate cancer is the most diagnosed cancer in men and multiple risk factors and genetic alterations have been described. The TMPRSS2-ERG fusion event and the overexpression of the transcription factor ERG are present in approximately 50% of all prostate cancer patients, however, the clinical outcome is still controversial. Prostate tumors produce various soluble factors, including the pleiotropic cytokine IL-6, regulating cellular processes such as proliferation and metastatic segregation. Here, we used prostatectomy samples in a tissue microarray format and analyzed the co-expression and the clinicopathologic data of ERG and IL-6 using immunohistochemical double staining and correlated the read-out with clinicopathologic data. Expression of ERG and IL-6 correlated strongly in prostate tissue samples. Forced expression of ERG in prostate tumor cell lines resulted in significantly increased secretion of IL-6, whereas the down-regulation of ERG decreased IL-6 secretion. By dissecting the underlying mechanism in prostate tumor cell lines we show the ERG-mediated up-regulation of the prostanoid receptors EP2 and EP3. The prostanoid receptor EP2 was overexpressed in human prostate cancer tissue. Furthermore, the proliferation rate and IL-6 secretion in DU145 cells was reduced after treatment with EP2-receptor antagonist. Collectively, our study shows that the expression of ERG in prostate cancer is linked to the expression of IL-6 mediated by the prostanoid receptor EP2. | ||
| 650 | 4 | |a Aged | |
| 650 | 4 | |a Biomarkers, Tumor | |
| 650 | 4 | |a Cell Line, Tumor | |
| 650 | 4 | |a Disease-Free Survival | |
| 650 | 4 | |a Down-Regulation | |
| 650 | 4 | |a Gene Expression Regulation, Neoplastic | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Interleukin-6 | |
| 650 | 4 | |a Male | |
| 650 | 4 | |a Middle Aged | |
| 650 | 4 | |a Prostate | |
| 650 | 4 | |a Prostatectomy | |
| 650 | 4 | |a Prostatic Neoplasms | |
| 650 | 4 | |a Receptors, Prostaglandin E, EP2 Subtype | |
| 650 | 4 | |a Up-Regulation | |
| 700 | 1 | |a von Mässenhausen, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Queisser, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Vogel, Wenzel |e verfasserin |4 aut | |
| 700 | 1 | |a Andrén, Ove |e verfasserin |4 aut | |
| 700 | 1 | |a Kirfel, Jutta |e verfasserin |4 aut | |
| 700 | 1 | |a Duensing, Stefan |d 1967- |e verfasserin |0 (DE-588)1074044487 |0 (DE-627)830213007 |0 (DE-576)435550098 |4 aut | |
| 700 | 1 | |a Perner, Sven |e verfasserin |4 aut | |
| 700 | 1 | |a Nowak, Michael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The American journal of pathology |d New York [u.a.] : Elsevier, 1925 |g 186(2016), 4, Seite 974-984 |h Online-Ressource |w (DE-627)271352906 |w (DE-600)1480207-7 |w (DE-576)078591732 |x 1525-2191 |7 nnns |
| 773 | 1 | 8 | |g volume:186 |g year:2016 |g number:4 |g pages:974-984 |g extent:11 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ajpath.2015.12.009 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ILN_2013 | ||
| 912 | |a ISIL_DE-16-250 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_168 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2007 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2025 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_2031 | ||
| 912 | |a GBV_ILN_2034 | ||
| 912 | |a GBV_ILN_2037 | ||
| 912 | |a GBV_ILN_2038 | ||
| 912 | |a GBV_ILN_2039 | ||
| 912 | |a GBV_ILN_2044 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2059 | ||
| 912 | |a GBV_ILN_2064 | ||
| 912 | |a GBV_ILN_2065 | ||
| 912 | |a GBV_ILN_2068 | ||
| 912 | |a GBV_ILN_2070 | ||
| 912 | |a GBV_ILN_2086 | ||
| 912 | |a GBV_ILN_2098 | ||
| 912 | |a GBV_ILN_2106 | ||
| 912 | |a GBV_ILN_2108 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2112 | ||
| 912 | |a GBV_ILN_2113 | ||
| 912 | |a GBV_ILN_2116 | ||
| 912 | |a GBV_ILN_2118 | ||
| 912 | |a GBV_ILN_2119 | ||
| 912 | |a GBV_ILN_2122 | ||
| 912 | |a GBV_ILN_2129 | ||
| 912 | |a GBV_ILN_2143 | ||
| 912 | |a GBV_ILN_2144 | ||
| 912 | |a GBV_ILN_2147 | ||
| 912 | |a GBV_ILN_2148 | ||
| 912 | |a GBV_ILN_2152 | ||
| 912 | |a GBV_ILN_2153 | ||
| 912 | |a GBV_ILN_2188 | ||
| 912 | |a GBV_ILN_2232 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 936 | u | w | |d 186 |j 2016 |e 4 |h 974-984 |g 11 |
| 951 | |a AR | ||
| 952 | |d 186 |j 2016 |e 4 |h 974-984 |g 11 | ||
| 980 | |2 2013 |1 01 |x DE-16-250 |b 3656778841 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 04-05-20 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2016 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_9 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_11 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1505553520 |a Duensing, Stefan | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416740848 |a Chirurgische Universitätsklinik | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_7 | ||